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A B S T R A C T
Background: Differential treatment allocation may impact on clinical phenotype in MS and in turn upon quality
of life (QoL).
Objectives: (a) Investigate the association between disease-modifying drugs (DMDs) use and relapse frequency,
disability, clinically significant fatigue, and physical and mental health-related QoL among participants with MS
residing in Australia and New Zealand (NZ); (b) assess whether these associations differed between Australia and
NZ.
Methods: Disability and fatigue were measured by PDDS and FSS, respectively. QoL was assessed by MSQOL-54.
Associations were assessed by binomial and multinomial logistic regression, as appropriate. Multivariable
models were adjusted for demographic and clinical covariates, as appropriate.
Results: 837 participants (627 from Australia; 210 from NZ) were identified from an online cohort of people with
MS. First- and second-generation DMD use was associated with higher adjusted-odds of fatigue and disability,
though not with 12-month relapse number. DMD use was not independently associated with physical or mental
QoL. The association of first-generation DMD use with moderate disability differed between nations, such that
treatment was associated with lower odds in Australia but not in NZ; a similar but a small difference was found
for severe disability. No differences were seen in the DMD association with relapse number, nor with fatigue or
QoL, between Australia and NZ.
Conclusion: The differential treatment allocation associations in NZ are evident in the DMD-disability associa-
tion, but there is no evidence that this treatment regimen has negative associations with fatigue, mood, or QoL.
1. Introduction
Multiple sclerosis (MS) is an incurable, lifelong inflammatory dis-
ease of the central nervous system associated with axon degeneration
and demyelination in the brain and spinal cord.(Compston et al., 2005)
Disease-modifying drugs (DMDs) have been demonstrated to reduce the
frequency and severity of clinical attacks or relapses, and there are
emerging data indicating that they may limit the accumulation of dis-
ability.(Lizak et al., 2017; Tur et al., 2018; Vargas and Tyor, 2017;
Vidal-Jordana, 2018) The side effects of these medications, which can
vary by DMD, frequently render them intolerable for people living with
MS.(Broadley et al., 2014; Subei and Ontaneda, 2015; Vargas and Tyor,
2017; Winkelmann et al., 2016) Moreover, though ocrelizumab has
now been demonstrated to have efficacy in primary progressive MS, this
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is the only such drug available for people with progressive MS types.
The more recently released second-generation DMDs have advantages
in terms of ease of administration and efficacy when compared with
drugs such as the interferons, but nonetheless have side effect profiles
of concern.(Vargas and Tyor, 2017)
Of particular interest here, there are regional differences in the
availability of these DMDs. For example, first and some second gen-
eration DMDs were listed for use in MS by the Pharmaceutical Benefits
Advisory Committee in Australia in 2012, but only first generation
DMDs were listed for use in MS in New Zealand (NZ) by the
Pharmaceutical Management Agency (PHARMAC) at that time, though
second-generation DMDs have become available since. This situation
creates a natural setup where treatment exposures vary between two
otherwise quite similar regions, both in terms of population, medical
infrastructure, and other characteristics.(Taylor et al., 2010; Taylor
et al., 2013) In this fashion, we can assess the relationship of DMD use
with various clinical outcomes in MS and whether these relationships
differ between nations. It is not unreasonable to expect some such
differences to be evident—the requirements for prescribing DMDs in MS
are much stricter in NZ, in terms of disability level and relapse number
in the previous 1–2 years, these independently assessed by committee,
and there are stopping criteria to discontinue therapy in those where
progression occurs despite treatment.(Pharmaceutical Management
Agency, 2012, 2014). In Australia, on the other hand, public subsidy of
MS medications is much more at the discretion of the treating physi-
cian, essentially only requiring diagnosed MS and having had two di-
agnosed relapses in the preceding two years(Department of Health and
Ageing, 2012). What is uncertain is whether this differential treatment
allocation impacts negatively on other elements of clinical course,
particularly fatigue or patient quality of life (QoL).
While DMDs have been demonstrated to impact on disability and
relapse, other aspects of clinical course, including fatigue, and quality
of life, can only be treated indirectly via immunomodulation of clinical
course, if at all. Of these, fatigue is one of the most prevalent and de-
bilitating complications,(Johnson, 2008; Nagaraj et al., 2013) affecting
up to 80% of people living with MS. Health-related QoL in people with
MS is often significantly lower than comparator populations, and like-
wise correlates strongly with clinical severity and disease course.
(Janardhan and Bakshi, 2002; Pittion-Vouyovitch et al., 2006; Wynia
et al., 2008) Since fatigue, mood, and QoL are strongly impacted by
relapse and disability in MS,(Amato et al., 2001; Janardhan and Bakshi,
2002) the differential allocation of DMDs could potentially have a ne-
gative impact on QoL, both directly due to untreated MS symptoms and
vicariously via impacts of MS on lifestyle and independent living.
In this study of people living with MS in Australia and NZ, we aimed
to (1) investigate the association between DMD use and clinical out-
comes among people living with MS residing in Australia and NZ; (2)
assess whether these associations differed significantly between
Australia and NZ.
2. Materials and methods
2.1. Participants and recruitment
The participants of this study were from the international HOLISM
(Health Outcomes and Lifestyle in a Sample of people with Multiple
Sclerosis) study in 2012 (Hadgkiss et al., 2013). The aim was to explore
the relationship of current lifestyle with clinical outcomes and quality
of life among people living with MS. The methodology of this study has
been described previously, but briefly, participants were recruited via
online forums and related venues to participate in an online survey of
the demographic, clinical and lifestyle characteristics of people living
with confirmed MS. Participants were included in the HOLISM baseline
study if they had doctor-diagnosed MS and were aged ≥18 years. The
HOLISM study was approved by St Vincent's Hospital Melbourne
Human Research Ethics Committee (LRR 055/12) and The University of
Melbourne Health Sciences Human Ethics Sub-Committee (Ethics ID:
1545102). The present analysis is circumscribed to include only parti-
cipants who reported residing in Australia or New Zealand at the time
of survey completion.
2.2. Data collection and tools used
2.2.1. DMD use
We presented survey participants with a list of MS-specific disease-
modifying therapies, including immunomodulatory and symptom-
ameliorating medications then available internationally. However,
given the focus of the present analysis on Australia and NZ, we will
constrain DMDs to the medications then available in these nations.
Thus, we classified first generation DMDs to include interferon-β and
glatiramer acetate medications, and second generation DMDs to include
fingolimod, cladribine, and natalizumab. DMD use was classified into
three groups: (a) no DMD use; (b) first-generation DMD use only; and
(c) second-generation DMD use, with or without first-generation DMD
use.
2.2.2. Clinical outcomes
Relapse number in the preceding year was queried, including the
overall number and those diagnosed as valid relapses by a medical
practitioner; only the latter are included here. For analyses, we cate-
gorised relapse number into three groups: (a) no relapse in the pre-
ceding year, (b) 1 relapse in the preceding year, (c) ≥2 relapses in the
preceding year. Disability was assessed using the Patient-Determined
Disease Steps (PDDS) scale,(Hohol et al., 1995) which has been vali-
dated against the Expanded Disability Status Scale (EDSS). A PDDS
score of 1–3 was indicative of mild disability, 4–6 indicative of gait
disability (moderate disability), and 7–8 indicative of severe mobility
disability (severe disability). Fatigue was assessed using the Fatigue
Severity Scale (FSS),(Krupp et al., 1989) a mean score ≥4 indicative of
clinically significant fatigue. Depression risk was assessed using the
Patient Health Questionnaire-2, a score of 3 or more indicating a po-
sitive depression screen.(Lowe et al., 2005) Quality of life was assessed
using the MSQOL-54, which estimates two core subdomains of physical
QoL and mental QoL (Vickrey, 1995).
2.2.3. Other lifestyle factors
Participants were queried as to their current smoking status (never/
former/current). Alcohol intake was queried, both frequency and ty-
pical number of standard drinks per sitting, this used to estimate an
alcohol load which we categorised as (a) high:> 30g /day for females
and> 45g /day for males; (b) moderate: up to 30g /day for females and
up to 45g /day for males; (c) low:< 15g / week.(Liang et al., 2012) We
assessed physical activity using the short form of the International
Physical Activity Questionnaire (IPAQ-SF) (Craig et al., 2003), the re-
sulting metabolic equivalent of task (MET) minutes categorising parti-
cipants into high-active (vigorous-intensity active on at least 3 days, or
7 days of walking, or moderate or vigorous activity), moderate-active (3
or more days of vigorous activity of at least 20 minutes per day, or 5 or
more days of moderate or higher intensity activity or walking of at least
30 minutes per day) and low-active (less active than the moderate ca-
tegory). We also queried whether participants took vitamin D and/or
omega-3 supplements, as well as the type and dose thereof. Anti-
depressant and anxiolytic prescription medication use was also queried.
We assessed diet quality using the Diet Habits Questionnaire (DHQ),
modified slightly to remove redundant questions on alcohol and also
questions on salt intake, as described previously.(Hadgkiss et al., 2015)
Total DHQ score ranged from 20 to 100, a score of 100 indicating the
healthiest dietary habits. Finally, we queried participants’ meditation
frequency, categorised as never, less than once per week, 1–4 times per
week, and ≥5 times per week.
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2.3. Data analysis
The characteristics of the cohort were summarised using mean
(standard deviation) and number (percentage) for continuous and ca-
tegorical variables respectively.
Association of DMD use and country with categorised relapses (1
relapse vs no relapse; 2 or more relapses vs no relapse), disability
(moderate vs mild; severe vs mild), clinically significant fatigue, posi-
tive depression screen, and physical and mental QoL was explored using
binomial or multinomial logistic regression (for categorical outcomes)
and linear regression (for continuous outcomes). Models were adjusted
for age, sex, MS type, disability, fatigue, ongoing relapse symptoms, and
antidepressant medication use, as appropriate. Analyses were con-
strained to where data were available for all model covariates (com-
plete case analysis).
Interactions were used to assess whether associations of DMD dif-
fered between Australia and NZ. Stratum-specific associations of DMD
with outcomes are presented for Australia and NZ.
Given as our primary analyses were based on an a priori hypothesis
that treatment associations with clinical outcomes would differ by
country, results are not adjusted for multiple comparisons.
All analyses were performed using STATA/SE, version 15.1
(StataCorp, College Station, USA).
4. Results
4.1. Cohort characteristics
A total of 837 people living with MS in in Australia and NZ, of which
627 (74.9%) were from Australia and 210 (25.1%) from NZ. Half
(50.3%) of respondents took first generation DMDs, while 15.8% were
using second-generation DMDs. As would be expected from the differ-
ential treatment regimes, a larger proportion of participants in NZ than
Australia were not using any DMDs (60.1% vs 25.0%); more similar
proportions were using first-generation DMDs in NZ and Australia
(37.4% vs 54.7%), but the proportion using second-generation DMDs
was much smaller in NZ than Australia (2.5% vs 20.3%, p value<
0.001).
The majority of respondents were female (81.6%), and of mean age
47.1 years (SD: 10.8). A majority (60.1%) of participants had mild
disability (PDDS 1–3), while roughly one-third had moderate disability
and 7.6% had severe disability. Nearly half of participants had had at
least one relapse in the preceding year, half of these having had two or
more. Sixty-two percent of respondents had clinically significant fa-
tigue. The mean physical and mental QoL were 64.1 (SD: 20.1) and 70.9
(SD: 19.8), respectively. Other cohort characteristics can be found in
Table 1.
4.2. Relapse number in the preceding year
Relapse number in the preceding year was not significantly asso-
ciated with DMD use, though on adjustment for age, sex and MS type,
first-generation DMD use was associated with a significantly lower odds
of having had 1 relapse in the preceding year (p = 0.035); a similar
association with 2+ relapses in the preceding year did not reach sig-
nificance (p = 0.33) (Table 2). The odds of having 1 or 2+ relapses in
the preceding year did not vary between Australia and NZ.
4.3. Disability
As in Table 3, the odds of having moderate or severe disability did
not significantly vary by DMD medication use. However, on controlling
for age, sex, MS type and whether participants had ongoing symptoms
from a recent relapse, the odds of having moderate disability were
higher among those on first-generation (p = 0.089) and second-gen-
eration (p = 0.001) DMDs, this change due largely to the impact of
adjusting for age. Second-generation DMD use was associated with an
even stronger association with severe disability (p = 0.001), though
first-generation DMD use was not associated (p = 0.56). The odds of
moderate disability were significantly greater among NZ participants
(p < 0.001), persisting on adjustment, though no significant difference
between nations was seen for severe disability. Further adjustment for
lifestyle factors did not attenuate these associations (data not shown).
4.4. Clinically significant fatigue
The odds of clinically significant fatigue, as defined by FSS≥4, was
significantly higher among those on second-generation (p = 0.015)
DMDs, persisting on adjustment for age, sex, MS type, disability level,
and whether participants were experiencing ongoing symptoms from a
recent relapse. A similar association was seen for first-generation DMDs
(p = 0.057), becoming significant on adjustment (p = 0.016; Table 4).
No differences in clinically significant fatigue were seen between Aus-
tralia and NZ. No associations materially differed on further adjustment
for lifestyle factors (data not shown).
4.5. Depression screen
The odds of positive depression screen, as measured by a PHQ-2
score> 2, while not significantly different among those using first-
generation DMDs, were two-fold higher among those using second-
generation DMDs, though this association attenuated and became
nonsignificant on adjustment for age, sex, MS type, disability level,
fatigue, and antidepressant medication use (Table 5). While depression
risk did not significantly differ between Australia and NZ in univariable
models, on adjustment for demographics and clinical features, the odds
of depression was significantly lower among NZ participants
(p = 0.032).
4.6. Physical and mental health-related quality of life
As in Table 6, first-generation DMD use was not significantly asso-
ciated with physical nor mental QoL, either alone or on adjustment for
age, sex, MS type, disability level, clinically significant fatigue, and
whether participants were experiencing ongoing symptoms from a re-
cent relapse. Second-generation DMD use, however, was associated
with significantly lower physical (p = 0.007) and mental (p = 0.007)
QoL, the association with physical QoL persisting on adjustment, while
that with mental QoL attenuated and became nonsignificant. Interest-
ingly, while neither physical nor mental QoL scores significantly dif-
fered between Australian and NZ participants, on controlling for de-
mographic and clinical covariates, NZ participants had a significantly
higher physical QoL (p = 0.004); similarly, higher mental QoL among
NZ participants did not reach significance (p = 0.13).
4.7. Differences in DMD-outcome associations between Australia and NZ
In assessing differences in the associations of DMD and outcomes
between nations (Table 7), no significant differences were seen in the
associations with relapse number in the preceding year, as seen in the
aggregate. First-generation DMD use was associated with a significantly
higher frequency of moderate disability in NZ (p = 0.001), as in all
persons, while no significant association was seen in Australian parti-
cipants (p = 0.072), this difference significant (pinteraction = 0.036). An
analogous trend was seen for severe disability – first-generation DMD
being associated with greater disability risk in NZ but not Australia,
though this interaction did not reach significance (pinteraction = 0.14).
There was no statistical difference in the associations of second-gen-
eration DMDs and moderate disability between nations
(pinteraction = 0.49), though the small numbers precluded quantitative
assessment of this interaction for severe disability. The association of
first-generation DMD use with clinically significant fatigue was not
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materially different between Australia and NZ (pinteraction = 0.29);
small sample size precluded examination of inter-nation differences in
the association of second-generation DMDs and fatigue. Neither first
nor second-generation DMD use was significantly associated with po-
sitive depression screen in either Australia or NZ participants, and ac-
cordingly no significant differences were seen between nations. Simi-
larly, there was no evidence of difference in the associations of DMDs
and physical or mental quality of life in Australia or NZ, and likewise no
significant differences between nations were evident.
Results evaluating treatment duration showed generally similar re-
sults: in Australia, longer DMD treatment durations were associated
with lower risks of having more relapses and moderate disability, while
in NZ there was a trend towards a greater risk of having more relapses
and of moderate and severe disability, the differences for disability
evident (pinteraction = 0.009 for moderate, pinteraction = 0.082 for se-
vere). Of note, second-generation DMD use, while not associated with
relapse number, was associated with greater risk of moderate and se-
vere disability in Australia (NZ could not be quantitatively evaluated
due to small cell sizes). Alongside the inverse associations seen between
first-generation DMDs and disability, this may reflect treatment
switching from first to second-generation DMDs in Australia. No asso-
ciations between DMD treatment duration and fatigue or disability
were evident in either Australia or NZ. Importantly, and in agreement
with the results seen for overall DMD usage, no significant differences
in the associations of first and second-generation DMD treatment
duration and physical (pinteraction = 0.47, pinteraction == 0.65) and
mental QoL (pinteraction = 0.73, pinteraction = 0.39) were evident be-
tween nations.
5. Discussion
Here, we have endeavoured to use the differential allocation of
DMD therapies in MS between Australia and New Zealand to assess
whether a more restricted allocation of DMDs in NZ impacted nega-
tively on fatigue and quality of life. We found that, while the associa-
tion of DMDs with disability significantly differed between the two
nations, as expected given the different allocation regimes, there was no
evident impact on either fatigue, depression, or quality of life.
Australia and New Zealand share a similar geographic location and
a commonality of government and healthcare systems. Both have uni-
versal access to care for citizens and permanent residents, and thus,
there is not as much of a socioeconomic divide of healthcare access of
the sort seen in nations without national health insurance schema.
However, differences exist in treatment allocation between Australia
and NZ. NZ's smaller economy than that of Australia means that their
triage of medical infrastructure has more stringent criteria to be met
before treatment can be paid for by the state, and likewise criteria in
which treatment will be discontinued where it is not impacting on
disease.(Dew and Davis, 2014; Grocott et al., 2013; Taylor and Wonder,
2015; Wonder and Milne, 2011) These criteria are almost wholly absent
in Australia where medical practitioners may prescribe pharmaceuticals
which are then costed in some part to Medicare. The concern here is not
to impugn the rationality of NZ's treatment allocation regime. Indeed,
while it is a topic of lively debate,(McNaughton et al., 2006; Taylor and
Wonder, 2015) others have shown that the allocation rationales of
PHARMAC are sound.(Evans et al., 2016; Grocott et al., 2013) Rather
the aim here was to examine whether it has follow-on negative impacts
Table 1
Cohort characteristics, overall and by country.
Australia New Zealand Total P value
n/N (%) n/N (%) n/N (%)
Sex
Male 103/587 (17.6%) 42/200 (21.0%) 145/787 (18.4%)
Female 484/587 (82.5%) 158/200 (79.0%) 642/787 (81.6%) 0.28
Age, years (mean (SD)) 46.7 (10.8) 48.3 (10.8) 47.1 (10.8) 0.063
Smoking status
Never 304/589 (51.6%) 93/198 (47.0%) 397/787 (50.4%)
Former smoker 238/589 (40.4%) 87/198 (43.9%) 325/787 (41.3%)
Current smoker 47/589 (8.0%) 18/198 (9.1%) 65/787 (8.3%) 0.52
Alcohol consumption*
Low 344/587 (58.6%) 94/197 (47.7%) 438/784 (55.9%)
Moderate 236/587 (40.2%) 102/197 (51.8%) 338/784 (43.1%)
High 7/587 (1.2%) 1/197 (0.5%) 8/784 (1.0%) 0.015
Physical activity
Low active 226/583 (38.8%) 78/196 (39.8%) 304/779 (39.0%)
Moderate active 185/583 (31.7%) 68/196 (34.7%) 253/779 (32.5%)
High active 172/583 (29.5%) 50/196 (25.5%) 222/779 (28.5%) 0.53
Vitamin D supplementation *
None 81/572 (14.2%) 14/182 (7.7%) 95/754 (12.6%)
1–2000 IU 156/572 (27.3%) 53/182 (29.1%) 209/754 (27.7%)
2001–5000 IU 213/572 (37.2%) 62/182 (34.1%) 275/754 (36.5%)
>5000 IU 122/572 (21.3%) 53/182 (29.1%) 175/754 (23.2%) 0.033
Meditation frequency
Never 207/585 (35.4%) 86/197 (43.7%) 293/782 (37.5%)
Less than once per week 166/585 (28.4%) 47/197 (23.9%) 213/782 (27.2%)
1 – 4 times per week 148/585 (25.3%) 46/197 (23.4%) 194/782 (24.8%)
5 or more times per week 64/585 (10.9%) 18/197 (9.1%) 82/782 (10.5%) 0.21
Physical health-related quality of life (mean (SD)) 64.0 (20.5) 64.6 (19.0) 64.1 (20.1) 0.74
Mental health-related quality of life (mean (SD)) 70.4 (20.2) 72.2 (18.5) 70.9 (19.8) 0.30
DMD use*
None 148/591 (25.0%) 121/198 (60.1%) 267/789 (33.8%)
First-generation 323/591 (54.7%) 74/198 (37.4%) 397/789 (50.3%)
Second-generation 120/591 (20.3%) 5/198 (2.5%) 125/789 (15.8%) <0.0-
01
Results in boldface denote statistical significance (p < 0.05).
Note: Differences in denominators in cells reflect missing data for specified parameters.
⁎ Significance of differences of dichotomous and polytomous variables between Australia and NZ assessed by Chi-square tests. Differences of continuous variables
between Australia and NZ assessed by t test.
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on quality of life and clinical features for people living with MS most
directly impacting on QoL, namely fatigue.
Given the PHARMAC guidelines in NZ require minimum relapse
rates in the preceding year and minimum levels of disability,
(Pharmaceutical Management Agency, 2014) we expected to find sig-
nificant differences in the DMD associations with these outcomes when
comparing Australia and NZ. For disability, we showed precisely this,
with disability significantly more common among users of first-gen-
eration DMDs in NZ, while no association was seen in Australia.
Second-generation DMDs did not differ at all between nations but this
may reflect the smaller numbers on these treatments compared to the
more commonly used interferon and glatiramer acetate medications. At
the same time, however, we did not show any association between
DMDs and relapse number, nor a difference in that association between
Australia and NZ. This may reflect the self-reported nature of relapses,
participants having been queried on the number of doctor-diagnosed
relapses in the preceding year. This method is inherently subject to
recall bias, as well as inter-patient variability in reporting relapse
symptoms to medical practitioners. Also, since our measure of relapse
number was only in the year preceding the survey, it may be that pa-
tients established on therapy would not show a difference in the DMD-
relapse association, even despite differential inclusion criteria.
Of relevance to our study's aims, we found that both first and
second-generation DMDs were associated with a greater frequency of
clinically significant fatigue, but this association did not differ between
Australia and NZ. Importantly, we found no evidence of differences in
the association of DMD use with depression between Australia and NZ,
nor any difference in the association of DMDs with physical or mental
QoL, suggesting that the differential treatment allocation regime in NZ
does not adversely impact on mental health or quality of life, despite
restricting use to those with more active disease.
5.1. Strengths and limitations
This is the largest study examining DMD use and its associations with
clinical outcomes in the Australasian setting. The mode of recruitment,
however, may have led to a healthier and self-selected sample which may
not fully represent the broader population of people living with MS. The
demographic and disease characteristics of the sample are fairly com-
parable to other studies of MS, however, so while our cohort is healthier,
it is nonetheless useable for this purpose. The self-reporting of various
outcomes rather than objective measures in clinic is a limitation, since
subjectivity necessarily affects one's perceptions and thus, their reporting
of disability, fatigue and QoL-related parameters. However, all these
measures have been validated against corresponding clinical measures.
One feature which would have been of especial use in this analysis is
information about the dose and consistency of use of first and second-
generation DMDs over time, as well as the degree of adherence to the
specified treatment, which would have enabled us to better evaluate the
internal consistency and dose-dependency of associations with outcomes,
as well as to undertake sensitivity analyses constrained to those with
more consistent medication use. While the analyses described here were
based on a priori hypotheses, the number of tests – 42 – does mean there
is some potential for type-1 error. However, the fact that our main
conclusions derive from the absence of significant differences in the
DMD-outcome associations between Australia and NZ, this is less of a
concern than would be the case if we had drawn conclusions based on
significant results. Finally, it is worth noting that the small numbers of
patients on DMDs in NZ, particularly the second-generation DMDs, does
limit the ability to quantitatively assess the DMD-outcome associations,
so replication in other studies would be key. Further to this, the natural
experiment of Australia and NZ used in this paper will be used for a
similar purpose to examine disability progression, among other out-
comes, in the CompANZ Study being conducted presently (Claflin et al.,
2018). This study will compare clinical outcomes, mood and QoL be-
tween Australian and NZ participants with relapsing-remitting MS. It willTa
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be useful if this study confirms the findings here.
6. Conclusion
We investigated whether a more restricted DMD allocation in MS
negatively impacted on clinical course, fatigue and quality of life. We
found the expected differences in disability, but no differences were
seen in fatigue, depression, or quality of life. Thus, in this setting, there
appears to be no deleterious impact of more restrictive treatment al-
location on quality of life in MS.
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Table 3
Univariable and adjusted OR of characteristics of disability level (PDDS).
Gait/cane (moderate) disability vs normal/
mild disability
Major mobility support (severe) vs normal/
mild disability
Normal/Mild
disability (%)
Gait/Cane (moderate)
disability (%)
Major mobility
support (severe)
(%)
Univariable OR
(95% CI)
Adjusted OR *
(95% CI)
Univariable OR
(95% CI)
Adjusted OR * (95%
CI)
DMD use*
None 151/266 (56.8%) 92/266 (34.6%) 23/266 (8.7%) 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
First-generation 254/395 (64.3%) 117/395 (29.6%) 24/395 (6.1%) 0.76 (0.54, 1.06) 1.50 (0.94, 2.39) 0.62 (0.34, 1.14) 1.29 (0.55, 2.99)
p=0.11 p=0.089 p=0.12 p=0.56
Second-generation 67/125 (53.6%) 45/125 (36.0%) 13/125 (10.4%) 1.10 (0.70, 1.74) 2.69 (1.48, 4.88) 1.27 (0.61, 2.67) 5.22 (1.92, 14.22)
p=0.68 p= 0.001 p=0.52 p= 0.001
Country
Australia 377/593 (63.6) 172/593 (29.0) 44/593 (7.4) 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference]
New Zealand 100/201 (49.8) 85/201 (42.3) 16/201 (8.0) 1.86 (1.33, 2.62) 1.70 (1.13, 2.57) 1.37 (0.74, 2.53) 1.00 (0.47, 2.14)
p < 0.001 p=0.011 p=0.31 p=0.99
Results in boldface denote statistical significance (p < 0.05).
DMD multivariable model consisted of 758 observations; country multivariable models consisted of 758 observations (complete case analysis).
Note: Univariable results restricted to complete case analysis did not materially affect any results (data not shown).
⁎ Multinomial logistic regression after adjusting for age, sex, MS type, and whether participant was experiencing ongoing symptoms from a relapse in the previous
30 days.
Table 4
Univariable and adjusted OR of characteristics of clinically significant fatigue.
Clinically
significant fatigue
(%)
Univariable OR
(95% CI)
Adjusted OR *
(95% CI)
DMD use*
None 141/250 (56.4%) 1.00 [Reference] 1.00 [Reference]
First-generation 245/383 (64.0%) 1.37 (0.99, 1.90) 1.64 (1.10, 2.44)
p=0.057 p= 0.016
Second-
generation
81/116 (69.8%) 1.79 (1.12, 2.86) 1.81 (1.04, 3.15)
p=0.015 p=0.036
Country
Australia 346/558 (62.0%) 1.00 [Reference] 1.00 [Reference]
New Zealand 121/191 (63.4%) 1.06 (0.75, 1.49) 0.83 (0.56, 1.23)
p=0.74 p=0.36
Results in boldface denote statistical significance (p < 0.05).
Multivariable models consisted of 713 observations (complete case analysis).
Note: Univariable results restricted to complete case analysis did not materially
affect any results (data not shown).
⁎ Multivariable logistic regression after adjusting for age, sex, MS type, dis-
ability level, and whether participant was experiencing ongoing symptoms from
a relapse in the previous 30 days.
Table 5
Univariable and adjusted OR of characteristics of depression risk (PHQ-2 > 2).
Positive depression screen (PHQ-2≥3) Univariable OR (95% CI) Adjusted OR * (95% CI)
DMD use*
None 30/264 (11.4%) 1.00 [Reference] 1.00 [Reference]
First-generation 55/386 (14.3%) 1.30 (0.81, 2.09) 0.99 (0.59, 1.68)
p=0.29 p=0.98
Second-generation 27/122 (22.1%) 2.22 (1.25, 3.93) 1.41 (0.73, 2.72)
p= 0.006 p=0.31
Country
Australia 92/578 (15.9%) 1.00 [Reference] 1.00 [Reference]
New Zealand 20/194 (10.3%) 0.61 (0.36, 1.02) 0.54 (0.31, 0.95)
p=0.057 p=0.032
Results in boldface denote statistical significance (p < 0.05).
Multivariable models consisted of 707 observations (complete case analysis).
Note: Univariable results restricted to complete case analysis did not materially affect any results (data not shown).
⁎ Multivariable logistic regression after adjusting for age, sex, MS type, disability level, clinically significant fatigue, and use of antidepressant medication.
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Table 6
Univariable and adjusted OR of characteristics of physical and mental health-related quality of life
Physical health-related QoL Mental health-related QoL
Univariable β (95% CI) Adjusted β * (95% CI) Univariable β (95% CI) Adjusted β * (95% CI)
DMD use*
None 0.00 [Reference] 0.00 [Reference] 0.00 [Reference] 0.00 [Reference]
First-generation −1.48 (−4.98, 2.01) −2.08 (−4.80, 0.64) −1.71 (−4.85, 1.44) −0.17 (−3.31, 2.97)
p=0.41 p=0.13 p=0.29 p=0.91
Second-generation −6.67 (−11.40, −1.95) −4.12 (−7.75, −0.49) −5.83 (−10.08, −1.57) −3.05 (−7.19, 1.09)
p= 0.006 p = 0.026 p= 0.007 p=0.15
Country
Australia 0.00 [Reference] 0.00 [Reference] 0.00 [Reference] 0.00 [Reference]
New Zealand 0.61 (−3.05, 4.26) 3.83 (1.24, 6.41) 1.73 (−1.54, 4.99) 2.33 (−0.66, 5.32)
p=0.75 p = 0.004 p=0.30 p=0.13
Results in boldface denote statistical significance (p < 0.05).
Physical quality of life multivariable model consisted of 587 observations; mental quality of life multivariable model consisted of 680 observations (complete case
analysis).
Note: Univariable results restricted to complete case analysis did not materially affect any results (data not shown).
⁎ Multivariable linear regression after adjusting for age, sex, MS type, disability level, clinically significant fatigue, and whether participant was experiencing
ongoing symptoms from a relapse in the previous 30 days.
Table 7
Differences in DMD-outcome associations between Australia and New Zealand
DMD Use Australia NZ Test for difference
Relapses in the preceding yeara aOR (95% CI)
(1 relapse vs no relapse) None 1.00 [Reference] 1.00 [Reference]
First-generation 0.59 (0.34, 1.04) 0.56 (0.24, 1.30) p=0.91
Second-generation 0.74 (0.38, 1.42) 0.33 (0.03, 3.43) p=0.52
(2 or more relapses vs no relapse) None 1.00 [Reference] 1.00 [Reference]
First-generation 0.77 (0.43, 1.40) 1.00 (0.46, 2.15) p=0.59
Second-generation 0.78 (0.39, 1.59) 0.43 (0.04, 4.50) p=0.62
Disabilityb
(Gait/cane disability vs normal/mild disability) None 1.00 [Reference] 1.00 [Reference]
First-generation 1.45 (0.80, 2.65) 3.93 (1.81, 8.55) p= 0.036
Second-generation 3.35 (1.66, 6.79) 7.27 (0.87, 61.05) p=0.49
(Major mobility support vs normal/mild disability) None 1.00 [Reference] 1.00 [Reference]
First-generation 1.03 (0.36, 2.92) 3.64 (0.89, 14.83) p=0.14
Second-generation 5.17 (1.67, 15.99) ⁎⁎⁎ -
Clinically significant fatiguec None 1.00 [Reference] 1.00 [Reference]
First-generation 1.87 (1.14, 3.07) 1.19 (0.58, 2.44) p=0.29
Second-generation 1.89 (1.02, 3.52) ⁎⁎⁎ -
Depression risk (PHQ-2)d
Positive vs negative depression screen None 1.00 [Reference] 1.00 [Reference]
First-generation 0.68 (0.37, 1.28) 1.48 (0.52, 4.17) p=0.21
Second-generation 0.85 (0.41, 1.77) 9.18 (0.69, 122.14) p=0.081
β (95% CI)
Physical quality of lifee None 0.00 [Reference] 0.00 [Reference]
First-generation −0.12 (−3.48, 3.24) −3.05 (−7.85, 1.75) p=0.31
Second-generation −1.81 (−5.93, 2.30) −6.15 (−21.89, 9.59) p=0.60
Mental quality of lifee None 0.00 [Reference] 0.00 [Reference]
First-generation 0.26 (−3.60, 4.13) 1.10 (−4.43, 6.63) p=0.80
Second-generation −1.52 (−6.21, 3.17) −16.81 (−34.07, 0.46) p=0.091
Results in boldface denote statistical significance (p < 0.05).
⁎⁎⁎ Could not be quantitatively assessed due to small cell size.
a Adjusting for age, sex, and MS type.
b Adjusting for age, sex, MS type, and whether participant was experiencing ongoing symptoms from a relapse in the previous 30 days.
c Adjusting for age, sex, MS type, disability level, and whether participant was experiencing ongoing symptoms from a relapse in the .previous 30 days.
d Adjusting for age, sex, MS type, disability level, clinically significant fatigue, and use of antidepressant medication.
e Adjusting for age, sex, MS type, disability level, clinically significant fatigue, and whether participant was experiencing ongoing symptoms from a relapse in the
previous 30 days.
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educational workshops for people with MS.
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